BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Xanthus Pharmaceuticals, Inc. 

300 Technology Square

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-225-0522 Fax: 617-225-0525


SEARCH JOBS

View Clinical Trials from BioPharm Insight









 Company News
Antisoma PLC (ASM.L) To Acquire Xanthus Pharmaceuticals, Inc. For USD $52.2M 5/16/2008 8:45:16 AM    More...
Xanthus Pharmaceuticals, Inc.'s Symadex Demonstrates Ability to Increase Spinal Cord Remyelination in Multiple Sclerosis Model 12/11/2007 11:51:54 AM    More...
Xanthus Pharmaceuticals, Inc.' Xanafide Bypasses Multi-Drug Resistance Proteins in Acute Myeloid Leukemia 12/10/2007 9:00:03 AM    More...
European Commission Grants Orphan Drug Designation to Xanthus Pharmaceuticals, Inc.'s Xanafide for the Treatment of Acute Myeloid Leukemia 10/26/2007 10:28:49 AM    More...
Xanthus Pharmaceuticals, Inc. Presents Data from FLT3 Autoimmune Program Supporting Novel Cell-Targeted Mechanism for Disease Attenuation 10/15/2007 11:12:24 AM    More...
Xanthus Pharmaceuticals, Inc. to Present at the Biotechnology Industry Organization (BIO) Investor Forum 2007 Conference 10/3/2007 9:59:57 AM    More...
Xanthus Life Sciences Presents In Vitro Data Demonstrating That Symadex Is A Potent And Selective Inhibitor Of FLT3 9/15/2006 11:08:46 AM    More...
Xanthus Life Sciences Changes Name To Xanthus Pharmaceuticals, Inc. 2/22/2006 10:25:58 AM    More...
Xanthus Life Sciences' Symadex(TM) Shows Remyelination In Multiple Sclerosis Animal Model 2/13/2006 11:32:12 AM    More...
Xanthus Life Sciences To Provide Update At The Biotechnology Industry Organization (BIO) CEO & Investor Conference 2006 2/9/2006 12:59:04 PM    More...
1234